Opus Genetics Q2 revenue falls and misses estimates

Opus Genetics

06/08/2026 12:17

Overview
U.S. gene therapy developer's Q2 revenue fell and missed analyst expectations
Net loss widened from prior year, driven by higher R&D expenses and lower revenue
Company expects cash runway to support operations into 2029

Outlook
Opus Genetics expects OPGx-BEST1 Cohort 1 topline data in second week of September 2026
Company expects dosing in OPGx-LCA5 registrational trial to begin in Q4 2026
Opus Genetics projects cash runway to fund operations into 2029

Result Drivers
HIGHER R&D COSTS - Co said increased manufacturing and clinical expenses for IRD programs drove higher R&D costs
LOWER COLLABORATION REVENUE - Co said Q2 revenue decline was mainly due to lower reimbursement from Viatris collaboration
HIGHER COMPENSATION COSTS - Co said increase in G&A expenses was mainly due to higher employee compensation

Company press release: ID:nGNX3dJ1Pr

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$755,000
$2.47 mln (17 Analysts)
Q2 Net Loss
 
$8.10 mln
 
Q2 Operating Expenses
 
$17.24 mln
 
Q2 Operating Income
 
-$16.48 mln
 
Q2 Pretax Loss
 
$8.10 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Opus Genetics Inc is $10.00, about 164.6% above its August 5 closing price of $3.78

Reuters Recommended Reads
Aug 3 - Switzerland's CRISPR Therapeutics Q2 CASGEVY revenue jumps 151%, net loss narrows on FDA approval for expansion
Aug 5 - Editas Medicine Q2 net loss narrows and beats estimates
Aug 4 - Arrowhead Pharmaceuticals Q3 revenue jumps on REDEMPLO growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)